[go: up one dir, main page]

WO2004087044A3 - Cible medicamenteuse - Google Patents

Cible medicamenteuse Download PDF

Info

Publication number
WO2004087044A3
WO2004087044A3 PCT/US2003/040752 US0340752W WO2004087044A3 WO 2004087044 A3 WO2004087044 A3 WO 2004087044A3 US 0340752 W US0340752 W US 0340752W WO 2004087044 A3 WO2004087044 A3 WO 2004087044A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug target
monitoring
genes
useful
ifit1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/040752
Other languages
English (en)
Other versions
WO2004087044A2 (fr
Inventor
Ivan Plavec
Oksana Sirenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioseek LLC
Original Assignee
Bioseek LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioseek LLC filed Critical Bioseek LLC
Priority to AU2003303963A priority Critical patent/AU2003303963A1/en
Publication of WO2004087044A2 publication Critical patent/WO2004087044A2/fr
Publication of WO2004087044A3 publication Critical patent/WO2004087044A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des essais et des criblages pour la surveillance de l'expression de gènes impliqués dans la réponse inflammatoire, notamment IFIT1, et pour la surveillance de l'activité des produits de tels gènes. Ces essais et ces criblages sont utiles pour l'identification d'agents utiles pour le traitement d'une maladie inflammatoire.
PCT/US2003/040752 2002-12-20 2003-12-19 Cible medicamenteuse Ceased WO2004087044A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003303963A AU2003303963A1 (en) 2002-12-20 2003-12-19 Drug target

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43584802P 2002-12-20 2002-12-20
US60/435,848 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004087044A2 WO2004087044A2 (fr) 2004-10-14
WO2004087044A3 true WO2004087044A3 (fr) 2005-02-17

Family

ID=33131511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040752 Ceased WO2004087044A2 (fr) 2002-12-20 2003-12-19 Cible medicamenteuse

Country Status (2)

Country Link
AU (1) AU2003303963A1 (fr)
WO (1) WO2004087044A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1872293A4 (fr) * 2005-03-28 2010-01-06 Bioseek Inc Etablissement de profils d'ensembles de donnees biologiques de maladie cardio-vasculaire et d'inflammation cardio-vasculaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599669A (en) * 1990-10-16 1997-02-04 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
WO2002002807A2 (fr) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnostic des maladies associees a la signalisation cellulaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599669A (en) * 1990-10-16 1997-02-04 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
WO2002002807A2 (fr) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnostic des maladies associees a la signalisation cellulaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBANESI ET AL: "Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 28, 1998, pages 101 - 109, XP002982198 *
FESSLER ET AL: "A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 35, 30 August 2002 (2002-08-30), pages 31291 - 31302, XP002982197 *

Also Published As

Publication number Publication date
WO2004087044A2 (fr) 2004-10-14
AU2003303963A8 (en) 2004-10-25
AU2003303963A1 (en) 2004-10-25

Similar Documents

Publication Publication Date Title
EP1929073A4 (fr) Produits pharmaceutiques proteiques et utilisations de ceux-ci
NL1026892A1 (nl) ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
TWI347201B (en) Pharmaceutical products,uses thereof and methods for preparing the same
ITTO20021009A1 (it) Procedimento, sistema e prodotto informatico per la
AP2004003184A0 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same and methods for their use.
WO2004113277A3 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
SI1572708T1 (sl) Novi heterociklicni fluoroglikozidni derivati, zdravila, ki vsebujejo te spojine, in njihova uporaba
WO2005016227A3 (fr) Methodes et compositions pharmaceutiques servant a moduler l'activation d'heparanase et leurs utilisations
DE60325567D1 (de) Matrix für die modifizierte freigabe von aktiven substanzen
ATE524178T1 (de) Acylierte, heteroaryl-kondensierte cycloalkenylamine und deren verwendung als arzneimittel
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
WO2004071382A3 (fr) Heterocycles substitues
WO2006108075A3 (fr) Compositions et methodes accroissant la sensibilite aux medicaments et traitant les infections et maladies presentant une resistance aux medicaments
EP1319402A4 (fr) INHIBITEURS DE PRODUCTION D'IgE
EP1506965A4 (fr) Derives de propanolamine, procede de preparation de 3-n-methylamino-1-(2-thienyl)-1-propanols et procede de preparation de derives de propanolamine
NL1024676A1 (nl) HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan.
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2010019914A3 (fr) Agents anti-arythmie, procédés pour leur utilisation, procédés pour leur identification et kits pertinents
EP1961764A4 (fr) Produit d'addition de chaine de sucres et de peptide et produit pharmaceutique comprenant ce produit en tant que principe actif
DE60320811D1 (de) Setzung, plastisolzusammensetzung und produkt und formkoerper daraus
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
WO2007006591A3 (fr) Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP